Vanda Pharmaceuticals Announces Receipt Of Not Approvable Letter From FDA For Iloperidone

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced the receipt of a not approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application for iloperidone, an investigational atypical antipsychotic that was reviewed for the treatment of schizophrenia.

More: continued here

Filed under: Schizophrenia on July 31st, 2008